Combined use of bleomycin with radiation in the treatment of cancer.
1. The data accumulated in this study up to the present time shows that combined treatment of radiation and bleomycin in intra-oral carcinoma resulted in marked tumor regression and a significantly higher tumor disappearance rate as compared with radiotherapy alone. The 18 month survival rate for the combined treatment group exceeded the rate for the control group by about 20%. 2. In esophagal carcinoma, bleomycin in combination with radiation markedly improved the regression rate of polypoid type tumor, while no significant improvement was observed in other types. The 18 month survival rate of the control group was about 10% higher than that of the combined treatment group. 3. In bronchogenic carcinoma, no significant difference was observed in tumor regression or survival rate of either group.
D001761:Bleomycin / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000628:therapy; D004938:Esophageal Neoplasms / Q000628:therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy; D009062:Mouth Neoplasms / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*
D001761:Bleomycin